» LEARN ABOUT COVID-19 VARIANTS, VACCINES, TESTING, & VISITOR REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

NRG-GI002

Trial

Clinical Trial Title

Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Trial Status

Closed to Enrollment

Start Date

August 22, 2018

Trial Type

Cancer - Adult Oncology

Specific Condition

Rectal Cancer

Description

This randomized phase II trial studies how well veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib with combination chemotherapy and radiation therapy may kill more tumor cells and giving it before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Eligibility Criteria

  • Age ≥ 18 years at diagnosis
  • ECOG Performance Status of 0, 1, or 2
  • Diagnosis of adenocarcinoma of the rectum with the major portion of the tumor intact
  • Locally advanced Stage II or Stage III rectal cancer

Ineligibility Criteria

  • Clinical or radiologic evidence of metastatic disease
  • Sensory or motor neuropathy ≥ grade 2
  • History of prior invasive rectal malignancy, regardless of disease-free interval
  •  Other invasive malignancy within 5 years before randomization.
  • Chemotherapy within 5 years before randomization
  • Active inflammatory bowel disease

Treatment

Group 1: Patients will receive neoadjuvant FOLFOX x 8 cycles (each cycle = 2 weeks) → chemoRT (plus capecitabine) → surgical resection 8-12 wks later.

Group 2: Patients will receive neoadjuvant FOLFOX x 8 cycles (each cycle = 2 weeks) → chemoRT (plus capecitabine + Veliparib) → surgical resection 8-12 wks later.

IRB Number

NCI Central IRB

Principal Investigator Name

Andrew Kee, MD

Contact Name

Onoclogy Clinical Research

Phone

503-413-8199

Contact Fax

503-413-8199

Contact E-Mail

503-413-6920

Last Updated: Wednesday, January 27, 2021 12:56:50 PM